A comprehensive view of Gilead Sciences Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Gilead to present new data on HIV, COVID-19 and viral hepatitis treatments at the 31st Conference on Retroviruses and Opportunistic Infections; the analyses from nearly 80 studies include research on Biktarvy, Veklury, and Hepcludex

Gilead Sciences to purchase CymaBay Therapeutics for US$4.3B to expand its liver disease portfolio; deal give Gilead access to Seladelpar, a promising drug for the treatment of primary biliary cholangitis slated for potential FDA approval in 2024

Morningstar names Gilead a top dividend stock, noting stellar profit margins with HIV/hepatitis C virus portfolio, which requires small salesforce and inexpensive manufacturing; however, smart future acquisitions among factors needed to return to growth

Gilead to stop biologics expansion at Oceanside, California, site, will shift majority of biologics team to Foster City, California, by 2027 to consolidate development and manufacturing units; Gilead calls off plans for a new Oceanside facility

China approves Eisai's Leqembi injectable to treat minor dementia and cognitive dysfunction triggered by Alzheimer’s; China also approves Gilead's Descovy tablet for pre-exposure prophylaxis to lower the risk of HIV infection

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count